Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Profarma Distribuidora De Produtos Farmaceuticos's 3-Year RORE % for the quarter that ended in Mar. 2026 was 25.86%.
BSP:PFRM3's 3-Year RORE % is ranked better than 68.18% of 110
companies
in the Medical Distribution industry
Industry Median: 14.155
vs BSP:PFRM3: 25.86
Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Profarma Distribuidora De Produtos Farmaceuticos 3-Year RORE % Related Terms
Profarma Distribuidora De Produtos Farmaceuticos 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profarma Distribuidora De Produtos Farmaceuticos 3-Year RORE % Chart
Profarma Distribuidora De Produtos Farmaceuticos Annual Data
BSP:PFRM3 vs MCK, CAH, COR: 3-Year RORE % Comparison
For the Medical Distribution subindustry, Profarma Distribuidora De Produtos Farmaceuticos's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profarma Distribuidora De Produtos Farmaceuticos 3-Year RORE % vs Medical Distribution Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) has a 3-Year RORE % of 25.86 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Profarma Distribuidora De Produtos Farmaceuticos and its competitors. According to the industry distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #35 out of 110 companies in the Medical Distribution industry, placing it in the top 31.8%.
Is Profarma Distribuidora De Produtos Farmaceuticos' 3-Year RORE % too high?
Profarma Distribuidora De Produtos Farmaceuticos' current 3-Year RORE % is 25.86. The Medical Distribution industry median 3-Year RORE % is 14.16. Profarma Distribuidora De Produtos Farmaceuticos' value of 25.86 is 82.7% above this industry median. Based on the distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #35 out of 110 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Profarma Distribuidora De Produtos Farmaceuticos has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Profarma Distribuidora De Produtos Farmaceuticos' 3-Year RORE % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Profarma Distribuidora De Produtos Farmaceuticos ranks #35 out of 110 companies for 3-Year RORE %. This puts Profarma Distribuidora De Produtos Farmaceuticos in the upper half of its industry. The industry median 3-Year RORE % is 14.16. Profarma Distribuidora De Produtos Farmaceuticos' value of 25.86 is 82.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Distribution company?
The median 3-Year RORE % among Medical Distribution companies is 14.16, based on 110 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profarma Distribuidora De Produtos Farmaceuticos's current 3-Year RORE % of 25.86 is 82.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Profarma Distribuidora De Produtos Farmaceuticos and its competitors. For the Medical Distribution industry, the median 3-Year RORE % is 14.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profarma Distribuidora De Produtos Farmaceuticos's current 3-Year RORE % is 25.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profarma Distribuidora De Produtos Farmaceuticos stock overvalued right now?
Based on GuruFocus' analysis, Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.06, compared to a current price of R$6.88 — trading 14.6% below its estimated fair value. The current 3-Year RORE % is 25.86 and 82.7% above the Medical Distribution industry median of 14.16. Profarma Distribuidora De Produtos Farmaceuticos' overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3), the current 3-Year RORE % is 25.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profarma Distribuidora De Produtos Farmaceuticos (BSP:PFRM3) Overvalued in 2026?
Based on GuruFocus' analysis, Profarma Distribuidora De Produtos Farmaceuticos stock appears to be undervalued.
The current stock price of R$6.88 is trading 14.6% below its estimated GF Value™ of R$8.06.
GuruFocus considers Profarma Distribuidora De Produtos Farmaceuticos to be Modestly Undervalued.
Key valuation signals for BSP:PFRM3:
3-Year RORE %: 25.86
GF Value™: R$8.06 vs. price of R$6.88 (14.6% below fair value)
Industry Position: 82.7% above the Medical Distribution median (#35 of 110)
No single metric tells the full story. See the BSP:PFRM3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profarma Distribuidora De Produtos Farmaceuticos Business Description
Profarma Distribuidora De Produtos Farmaceuticos SA is a Brazil-based company. It is engaged in wholesale and distribution of pharmaceuticals, cosmetics and similar products, and toiletries. Profarma also holds interests in other companies, regardless of their business sector. The company through its logistics department distributes products in the South, Southeast, Northeast and Center-West regions of Brazil. The firm operates in the pharmaceutical distribution, hospital and specialty, retail segments.
75GF Score
Get the complete analysis for BSP:PFRM3
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PFRM3 has been successfully added to your 
